# Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

> **NCT04177680** · PHASE2 · COMPLETED · sponsor: **Matinas BioPharma Nanotechnologies, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Omega 3 pentaenoic acid
- **DRUG:** icosapent ethyl

## Key facts

- **NCT ID:** NCT04177680
- **Lead sponsor:** Matinas BioPharma Nanotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-03
- **Primary completion:** 2020-11-27
- **Final completion:** 2021-01-18
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177680, "Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04177680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*